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Greater understanding of the risk factors and mechanisms of incident dementia in stroke survivors is needed for prevention and
management. There is limited information on the long-term consequences and forms of incident dementia in older stroke
survivors. We recruited 355 patients aged 475 years from hospital-based stroke registers into a longitudinal study 3 months
after stroke. At baseline none of the patients had dementia. Patients were genotyped for apolipoprotein E and assessed annually
for cognition and development of incident dementia over up to 8 years of follow-up. The effect of baseline vascular risk factors
upon incidence of dementia and mortality were estimated by Cox proportional regression analyses adjusted for age and gender.
Standard neuropathological examination was performed to diagnose the ﬁrst 50 cases that came to autopsy. We found that the
median survival from the date of the index stroke was 6.72 years (95% conﬁdence intervals: 6.38–7.05). During the follow-up of
a mean time of 3.79 years, 23.9% of subjects were known to have developed dementia and 76.1% remained alive without
dementia or died without dementia. The incidence of delayed dementia was calculated to be 6.32 cases per 100 person years
whereas that for death or dementia was 8.62. Univariate and multivariate regression analyses showed that the most robust
predictors of dementia included low (1.5 standard deviations below age-matched control group) baseline Cambridge Cognitive
Examination executive function and memory scores, Geriatric Depression Scale score and three or more cardiovascular risk
factors. Autopsy ﬁndings suggested that remarkably 575% of the demented stroke survivors met the current criteria for
vascular dementia. Demented subjects tended to exhibit marginally greater neuroﬁbrillary pathology including tauopathy and
Lewy bodies and microinfarcts than non-demented survivors. Despite initial improvements in cognition following stroke in older
stroke survivors, risk of progression to delayed dementia after stroke is substantial, but is related to the presence of vascular risk
factors. Careful monitoring and treatment of modiﬁable vascular risk factors may be of beneﬁt in preventing post-stroke
dementia in the general population.
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Stroke and dementia individually are common, costly, and person-
ally often devastating to patients and their carers. One in six older
people suffer a stroke, and 30% of these individuals develop vas-
cular dementia or vascular cognitive impairment (Savva and
Stephan, 2010) and there is also a 9-fold increased risk of incident
dementia in the ﬁrst year after the ﬁrst-ever cerebral infarct rising
to a cumulative incidence of 23% within 10 years (Kokmen et al.,
1996). Stroke patients may also experience cognitive dysfunction
in the form of mild cognitive impairment. Recent meta-analysis
suggested the pooled prevalence estimates of post-stroke demen-
tia 51 year after the stroke ranged from 7.4% in population-
based studies of ﬁrst-ever stroke, in which pre-stroke dementia
was excluded, to 41.3% (29.6–53.1) in hospital-based studies of
recurrent stroke in which pre-stroke dementia was included. The
cumulative incidence of dementia after the ﬁrst year was slightly
greater (3.0%, 1.3–4.7) per year in hospital-based studies than
expected on the basis of recurrent stroke alone (Pendlebury and
Rothwell, 2009a). Multiple lesions over time and the characteris-
tics and complications of the stroke were found to be most
strongly associated with post-stroke dementia. It was therefore
suggested that stroke and recurrent strokes themselves, were more
important than underlying vascular risk factors. However, this
review included many studies that included post-stroke dementia
diagnosed within 3 months after stroke. It is possible that the
effect of background vascular risk factors will be more visible
when studying their long-term effects on more delayed onset of
post-stroke dementia, occurring after 3 months and much further
beyond. Few studies (Melkas et al., 2009; Narasimhalu et al.,
2009; Bejot et al., 2011) have followed participants over
42 years and therefore the long-term outcomes in terms of sur-
vival and underlying dementia processes still need elucidation.
The lack of association of individual vascular risk factors does
not take account of the potentially cumulative effect of multiple
vascular risk factors in some patients, inﬂuencing the progression
of both small vessel and large vessel disease. In addition, these
risk factors place the brain at risk over a prolonged period of time
after a stroke and therefore, long follow-up periods may be
required to delineate their effect more fully. Knowledge of the
effects of underlying vascular risk factors would be important for
optimum care of post-stroke survivors and secondary prevention in
reducing the burden of dementia (Pendlebury and Rothwell,
2009b).
We previously reported that although 41% of elderly survivors
who were dementia-free at 3 months post-stroke, were stable and
50% improved in cognition at 15 months post-stroke (Ballard
et al., 2003a), a substantial proportion of these subsequently pro-
gress to delayed dementia (Ballard et al., 2003a). Consistent with
other studies utilizing the 3-month design before follow-up
(Tatemichi et al., 1992; Pohjasvaara et al., 1998; Barba et al.,
2000), delayed post-stroke dementia was estimated to occur in
at least 25% of the subjects with various risk factors. The mech-
anisms accelerating cognitive decline and leading to delayed
dementia are unclear. These need to be elucidated if effective
treatment or management approaches to prevent cognitive
decline after stroke are to be developed (Leys et al., 2005).
More recently, we showed the association of medial temporal
lobe atrophy but not white matter hyperintensities with subse-
quent cognitive decline in post-stroke survivors (Firbank et al.,
2007). This suggests a greater role for Alzheimer-type pathology
than vascular pathology in delayed cognitive impairment after
stroke but, to our knowledge, there is no study to date reporting
the neuropathological outcomes of older post-stroke survivors
who develop dementia, and medial temporal lobe atrophy may
be an important component, but not uniquely associated
with Alzheimer-type pathology. Here, we hypothesized that
although the characteristics of the stroke would be a strong pre-
dictor of post-stroke dementia, the burden of vascular risk factors
will have an equally potent effect. We also report on the patho-
logical diagnosis in the ﬁrst 50 cases of this cohort that came to
autopsy.
Materials and methods
Study design and participants
Older (575 years) stroke patients (n = 706) were screened consecu-
tively from hospital-based stroke registers in Tyneside and Wearside in
the North East of England (Fig. 1). Potential participants were evalu-
ated at least 3 months after stroke [on the basis of the design of
Desmond et al. (2000) and to enable resolution of acute post-stroke
delirium] with a standardized battery comprised of medical history,
Mini-Mental State Examination score, assessment of neurological def-
icits, a blood screen, and review of CT brain scan undertaken at the
time of the stroke. Stroke was deﬁned according to the World Health
Organization deﬁnition and classiﬁed according to the Oxford
Community Stroke project classiﬁcation. We excluded those stroke
subjects who (i) were younger than 75 years of age; (ii) were with
signiﬁcant physical illness and disabilities that precluded neuropsy-
chological evaluation (e.g. visual impairment, aphasia, hemiparesis
affecting the hand used for writing); (iii) who had a Mini-Mental
State Examination score 524 at the 3-month assessment; (iv) had a
diagnosis of dementia according to DSM IIIR (Diagnostic and
Statistical Manual of Mental Disorders, Third Edition, Revised) criteria;
or (v) declined to take part. Following general practitioner approval
and discussion of the study, 355 of the original 706 subjects
were eligible for the post-stroke survivor study (Fig. 1). In addition
to this full cohort, a subgroup of 35 of the stroke survivors who
were already demented at baseline were recruited into a study of
falls in dementia, ongoing within the same department (Allan et al.,
2009). These patients received the same follow-up protocol as
the main cohort (described below). The brains (n = 6) of this sub-
group who came to autopsy were examined for comparative pur-
poses of neuropathological changes in those who presented with
immediate post-stroke dementia, as opposed to delayed dementia
after stroke.
Ethical approval was obtained from the Joint Ethics Committee of
Newcastle and North Tyneside Health Authority, the University of
Newcastle upon Tyne and the University of Northumbria at
Newcastle and participants gave written informed consent in accord-
ance with the Declaration of Helsinki.
Medical histories taken from the participants were supported
by review of hospital charts for diagnoses of previous stroke
3714 | Brain 2011: 134; 3713–3724 L. M. Allan et al.(including whether there was any residual disability from previous
stroke), hypertension (a documented history of blood pressure
4140/90mmHg or treatment of hypertension), atrial ﬁbrillation,
ischaemic heart disease, peripheral vascular disease,
hypercholesterolaemia, diabetes (documented or treated) and history
of smoking prior to stroke. Table 1 provides a list of the cardiovascular
risk factors including history of smoking. The characteristics of the full
cohort have been described previously (Ballard et al., 2003a, b).
Figure 1 Flow chart showing numbers screened, recruited and numbers of assessments at each year of the study, together with
deaths and withdrawals. Where totals show ‘still in study’, this refers to individuals who have so far completed less than 5–8 years of
follow-up but who have not yet died or withdrawn from the study. MMSE = Mini-Mental State Examination; VaD = vascular dementia.
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All participants completed a baseline neuropsychological assessment
including Cambridge Cognitive Examination (CAMCOG) section B
(mental disorders in the elderly), which is a standardized paper and
pencil test (maximum score, 107) for global cognitive performance.
The schedule includes subscores for memory (27 points), orientation
(10 points), language comprehension (9 points), language expression
(21 points), attention (7 points), praxis (12 points), calculation
(2 points), abstract thinking (8 points) and perception (11 points).
A separate executive function domain was scored out of 28 points
including supplementary questions in the revised version. As in our
previous report (Ballard et al., 2003a), mild cognitive impairment
based on Petersen criteria were applied: those with cognitive scores
41.5 standard deviations (SD) below an age-matched control group
were deﬁned as having amnestic mild cognitive impairment
(CAMCOG memory subscore 413) and/or non-amnestic mild cogni-
tive impairment (CAMCOG executive subscore 417). In separate
analyses, participants with a total CAMCOG score 580 were deﬁned
as having cognitive impairment with no dementia (CIND). Other com-
ponents of the battery included the Cognitive Drug Research compu-
terized battery, the Boston Naming Test, the FAS Verbal Fluency Test,
activities of daily living assessed with the Bristol scale, and depression
assessed with the DSM IV criteria for depression, the Geriatric depres-
sion scale and the Cornell scale.
Neuropsychological evaluations were repeated annually, as in the
baseline assessment, during a follow-up period of up to 8 years. If
the participant was too impaired to complete a Mini-Mental State
Examination, or their score was 424, had fallen by 52 points or
they had other evidence or suspicion of dementia, the assessor com-
pleted the Clinical Dementia Rating scale and IQCODE, with an in-
formant. All assessments were reviewed by the assessor and a senior
clinician (old age psychiatrist or geriatrician) to determine whether the
participant met the DSM IV criteria for dementia. Vital status and
dates of death were established immediately prior to analysis of the
data by making use of all available sources (next of kin, care home
records, hospital notes, primary care physician), even if the participant
had withdrawn from the study prior to death.
The apolipoprotein genotype for each participant was determined as
described previously (Ballard et al., 2004).
Neuropathological examination and
dementia diagnoses
Brains were retrieved from a total of 56 stroke survivors who came to
autopsy. Six of these were demented at baseline (Fig. 1) but were
included in the assessment for comparative purposes. Table 4 provides
demographic details and the highest and last CAMCOG scores. In the
majority of cases bronchopneumonia was recorded as the cause of
death.
Macroscopic and microscopic pathology was assessed with standar-
dized protocols as described (Kalaria et al., 2004; Ihara et al., 2010).
Brieﬂy, macroscopic infarcts were detected by visual inspection while
dissecting the brain, and their presence was subsequently conﬁrmed by
microscopy. Haematoxylin and eosin was used as standard stain for
general neuropathological assessment of the structure of the brain, and
for conﬁrmation/detection of the infarcts. In this study, any infarct
55mm in diameter was deﬁned as a microinfarct. Gallyas and
Bielschowsky’s silver impregnation and tau immunohistochemistry were
applied to assess neuritic plaques and neuroﬁbrillary tangles for the
‘CERAD’ plaque score and ‘Braak and Braak’ neuroﬁbrillary tangle
staging. Additional staining included  -synuclein, ubiquitin and
TDP-43 immunohistochemistry.
A clinical diagnosis of whether the dementia syndrome was present
was made independently of neuropathological data prior to monthly
clinicopathological consensus meetings where clinicians met with the
pathologists to designate a ﬁnal diagnosis for autopsied subjects. In all
cases, additional pathologies such as Alzheimer’s disease and dementia
with Lewy bodies were noted. The pathological diagnosis of vascular
dementia was then assigned if there was clinical evidence of dementia
(DSM IV) and the presence of multiple or cystic infarcts involving cor-
tical and subcortical structures, border-zone infarcts, lacunae, micro-
infarcts and small vessel disease in the general absence of a high
burden of neuroﬁbrillary pathology i.e. Braak staging 5IV (Kalaria
et al., 2004) or obvious other primary neurodegenerative disease,
and consistent with the clinical diagnostic criteria proposed by others
(Chui et al., 1992, 2000; Roman et al., 1993; Gold et al., 2002). After
breakdown by diagnostic subgroups, the number of autopsies did not
permit generation of sensitivity and speciﬁcity rates. Subjects were
designated as mixed when there was pathological evidence of cere-
brovascular disease with Alzheimer’s disease-type pathology, Lewy
bodies or tauopathy (frontotemporal lobar degeneration or progressive
supranuclear palsy). The cases with mixed cerebrovascular disease and
Alzheimer’s disease had a Braak stage of V or VI and moderate to
severe CERAD scores.
Neuroimaging
Fourteen participants who were MRI scanned in life at baseline also
come to autopsy. In these, the extent of medial temporal lobe atrophy
(right and left) was rated with a standardized scale (Scheltens et al.,
1992) from hard copies of the baseline T1-weighted coronal images.
This scale rates atrophy as 0, absent; 1, minimal; 2, mild; 3, moderate;
and 4, severe, based on the width of the surrounding CSF spaces
(temporal horn and choroid ﬁssure) and the height of the hippocampal
formation (which includes the hippocampus proper, subiculum,
Table 1 Baseline characteristics of post-stroke survivors
All participants
n 355
Age (years) mean (SD) 80 (4.10)
Male gender, n (%) 184 (51.8)
CAMCOG total score, mean (SD) 85.1 (8.96)
Total CAMCOG score 580 (CIND), n (%) 90 (25.4)
CAMCOG total memory score 417
(mild cognitive impairment), n (%)
50 (14.1)
CAMCOG total executive function
score 413, n (%)
168 (47.3)
Geriatric depression score, median (IQR) 3 (1–5)
Number of cardiovascular risk factors,
median (IQR)
2 (1–3)
Previous stroke, n (%) 104 (29.3)
Previous disabling stroke, n (%) 34 (9.6)
Ischaemic heart disease, n (%) 113 (31.8)
Hypertension, n (%) 193 (54.4)
Atrial ﬁbrillation, n (%) 55 (15.5)
Diabetes mellitus, n (%) 29 (8.2)
Hypercholesterolaemia, n (%) 45 (12.7)
Ever smoked, n (%) 207 (58.3)
APOE ”4 allele (one copy), n (%) 64/273(23.4)
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summed to give an overall combined medial temporal lobe atrophy
score (maximum score 8). All scans were rated by consensus between
two trained and experienced raters (M.J.F. and Dr Emma Burton,
Newcastle University).
Statistical analysis
In order to examine the associations between exposure to putative risk
factors for death or dementia, Cox proportional regression analyses
were used to obtain univariate proportional hazard ratios for each risk
factor, adjusted for age and sex, with time (days) from index stroke to
death, dementia and death or dementia as the dependent variables.
The date of onset of dementia was assumed to be at the midpoint
between the two assessments where dementia status changed. Hazard
ratios were given according to presence or absence of the risk factor,
or per point on quantitative scales as appropriate.
Following identiﬁcation in univariate models, signiﬁcant predictors of
death, dementia and death or dementia were entered into a multivari-
ate forward stepwise Cox regression model, P50.05 for entry, P40.1
for removal. Age and sex were included even if not signiﬁcant. Where
similar clinical features were described by more than one signiﬁcant
predictor, the predictor with the higher level of signiﬁcance in univari-
ate analyses was entered into multivariate analyses, in order to avoid
co-aggregation of predictors; e.g. baseline CIND rather than the base-
line CAMCOG score as both these tests assess cognition. Comparisons
or distributions between categories and numeric variables, e.g. age,
measures of pathological lesions, were assessed by the Mann–
Whitney U test or Chi square analysis. Associations between numeric
variables were determined by the Pearson or Spearman’s rank correl-
ation analysis (coefﬁcient estimate r).
Results
Participants
The 355 recruited subjects had a mean age of 80 (4.1) years
with 52% males. Hospital notes revealed that 19 (5.4%) patients
had sustained a total anterior circulation stroke, 145 (41%) a par-
tial anterior circulation stroke, 116 (33%) a lacunar stroke,
49 (14%) a posterior circulation stroke and 1 (0.3%) an unclassi-
ﬁable stroke. A summary of baseline characteristics of the partici-
pants is shown in Table 1.
Incidence of death, dementia and death
or dementia
The total duration of follow-up to establish vital status alone was
2039 person years (mean 5.74 years). During this time 176/355
(49.6%) participants were known to have died, 175 (49.3%)
remained alive and it was not possible to establish vital status in
four participants. Incidence of death was therefore 8.63 per 100
person years. The median survival from the date of the index
stroke was 6.72 years [95% conﬁdence intervals (CI): 6.38–7.05].
The total duration of follow-up to establish the incidence of
dementia was 1346 person years (mean 3.79 years). During this
time 85/355 (23.9%) participants were known to have developed
dementia (either before death or currently alive with dementia),
and 270 (76.1%) remained alive without dementia, or were with-
out dementia at death or withdrew from the study. Incidence
of dementia was calculated as 6.32 cases per 100 person years.
Table 2 shows the number and per cent of dementia cases at
each year of follow-up. The proportion of cases remaining in
the study with dementia continued to rise throughout the
follow-up period, such that although only 9.4% had dementia
after 1 year as in our previous report, after 3 years 21.4% cases
had dementia and by Year 7, 39.5% had dementia. One hundred
and forty-two participants withdrew from neuropsychological
follow-up during the study for reasons other than death; 11 had
dementia at the time of withdrawal. Participants who withdrew
from the study did not differ signiﬁcantly from other participants
in age, gender, baseline CAMCOG or the presence of baseline
CIND.
The total duration of follow-up to establish death or dementia
was 1346 person years (mean 3.79 years). During this time,
116 participants died or developed dementia before their last
examination of dementia status. Incidence of death or dementia
was therefore 8.63 per 100 person years.
Table 2 The number of incident cases of dementia each year
n No dementia (%) Dementia Cumulative
number of
incident
cases of
dementia
Established
cases (%)
Incident
cases (%)
Total
cases (%)
Baseline 355 355 (100) 0 (0) 0 (0) 0 (0) 0
Year 1 297 269 (90.6) 0 (0) 28 (9.4) 28 (9.4) 28
Year 2 251 212 (84.5) 24 (9.6) 16 (6.4) 40 (15.9) 44
Year 3 201 158 (78.6) 25 (12.4) 18 (9.0) 43 (21.4) 62
Year 4 163 127 (77.9) 32 (19.6) 4 (2.5) 36 (22.1) 66
Year 5 134 99 (73.9) 27 (20.1) 8 (6.0) 35 (26.1) 74
Year 6 95 69 ((72.6) 21 (22.1) 5 (5.3) 26 (27.3) 79
Year 7 43 26 (60.5) 12 (27.9) 5 (11.6) 17 (39.5) 84
Year 8 12 3 (25.0) 8 (66.7) 1 (8.3) 9 (75.0) 85
n=number of participants completing assessments.
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and death or dementia
Signiﬁcant univariate predictors of death, dementia and death or
dementia are shown in Table 3. Signiﬁcant predictors of death in
descending order included previous disabling stroke, number of
cardiovascular risk factors, CAMCOG executive function score,
the presence of CIND at baseline, history of smoking, baseline
Geriatric Depression Scale score and age.
Signiﬁcant predictors of dementia in descending order
included the presence of CIND at baseline, previous disabling
stroke, number of cardiovascular risk factors, baseline CAMCOG
memory and executive function scores, ischaemic heart disease
and Geriatric Depression Scale score. Figure 2A shows the survival
curve to dementia in the presence and absence of CIND at
baseline.
Signiﬁcant predictors of death or dementia in descending
order included three or more cardiovascular risk factors, the pres-
ence of CIND at baseline, previous disabling stroke, baseline
CAMCOG executive and memory function scores, Geriatric
Depression Scale score and age. Among the strongest vascular
risk factors were ischaemic heart disease and hypertension
(Table 3).
Multivariate predictors of death,
dementia and death or dementia
For the multivariate analyses, three different models were adopted
(Table 3). In the ﬁrst model predicting time to death, predictors
retained were age, smoking history, a history of previous disabling
stroke and baseline Geriatric depression score. In the second
model, predicting time to dementia, predictors retained were num-
ber of cardiovascular risk factors, CAMCOG total executive func-
tion score 413 and CAMCOG total memory score 417 (mild
cognitive impairment).
In the third model, predicting time to death or dementia, pre-
dictors retained were number of cardiovascular risk factors,
CAMCOG total executive function score 513 and baseline
Geriatric depression score (Table 3). Figure 2B–D illustrates the
differences in median survival times to death, dementia
and death or dementia by the number of cardiovascular risk
Table 3 Univariate and multivariate predictors of death, dementia and death or dementia
Baseline characteristic Death Dementia Death or dementia
Relative hazard
ratio (95% CI)
Relative hazard
ratio (95% CI)
Relative hazard
ratio (95% CI)
Univariate predictors
Age (years) 1.06 (1.02–1.10) 1.04 (0.99–1.10) 1.06 (1.01–1.11)
Male gender 1.13 (0.835–1.52) 0.68 (0.44–1.04) 0.825 (0.572–1.19)
CAMCOG score 580 (CIND) 1.64 (1.19–2.26) 4.02 (2.57–6.28) 2.96 (2.01–4.35)
CAMCOG total memory score 517.6
(mild cognitive impairment)
1.35 (0.902–2.03) 3.04 (1.81–5.10) 2.19 (1.36–3.52)
CAMCOG total executive function score 513.6 1.78 (1.31–2.40) 2.84 (1.80–4.48) 2.26 (1.55–3.29)
Geriatric Depression score 1.08 (1.03–1.13) 1.14 (1.07–1.22) 1.13 (1.07–1.19)
No. of cardiovascular risk factors:
1–2 versus none 2.23 (1.07–4.63) 2.13 (0.847–5.37) 2.17 (0.994–4.74)
53 versus none 2.75 (1.28–5.89) 3.61 (1.38–9.44) 3.37 (1.49–7.63)
Previous stroke (prior to the index episode) 1.70 (1.24–2.33) 1.74 (1.10–2.75) 1.65 (1.11–2.44)
Previous disabling stroke (prior to the index episode) 2.89 (1.92–4.33) 3.62 (2.01–5.651) 2.69 (1.57–4.60)
Ever smoked 1.58 (1.10–2.28) 1.11 (0.672–1.84) 1.45 (0.937–2.26)
Ischaemic heart disease 1.11 (0.810–1.53) 1.56 (1.00–2.43) 1.31 (0.890–1.92)
Hypertension 1.03 (0.753–1.40) 1.28 (0.815–2.02) 1.22 (0.829–1.79)
Atrial ﬁbrillation 0.935 (0.616–1.42) 0.988 (0.553–1.76) 1.06 (0.649–1.72)
Diabetes mellitus 1.13 (0.649–1.95) 1.54 (0.738–3.23) 1.22 (0.611–2.42)
Hypercholesterolaemia 0.772 (0.458–1.30) 0.672 (0.307–1.47) 0.635 (0.320–1.26)
APOE ”4 allele 1.04 (0.680–1.58) 1.47 (0.866–2.49) 1.37 (0.847–2.20)
Multivariate predictors
Age (years) 1.06 (1.02–1.11)
Previous disabling stroke 2.41 (1.58–3.72)
Ever smoked 1.47 (1.02–2.11)
Geriatric depression score 1.06 (1.01–1.12) 1.09 (1.02–1.15)
Number of cardiovascular risk factors
1–2 versus none 2.68 (0.83–8.70) 3.09 (1.12–8.51)
53 versus none 4.32 (1.28–14.6) 4.60 (1.61–13.1)
CAMCOG total executive function score 413 2.58 (1.54–4.28) 2.32 (1.53–3.52)
CAMCOG total memory score 417 (mild cognitive impairment) 2.27 (1.29–3.98)
Signiﬁcant results are shown in bold (P50.05).
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ticularly affected by the number of cardiovascular risk factors
(Table 3).
Neuropathological diagnoses of
post-stroke survivors
Age, gender and baseline CAMCOG scores did not differ signiﬁ-
cantly between those who did and did not donate their brains.
Of 176 deaths at the time of analysis of the survival data, 46
participants (26.1% of deaths) had donated their brains. A further
10 deaths resulted in brain donation following the analysis of the
survival data and these are also included in the neuropathological
analyses. Table 4 shows the age, gender distribution and neuro-
pathological diagnoses in demented stroke survivors among the
56 subjects who came to autopsy. Similar to data for the whole
cohort, the mean age of the demented subjects was greater but
the mean CAMCOG scores were lower (P50.05) than non-
demented subjects. The mean survival times from baseline stroke
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Figure 2 Survival curves to show time (A) to dementia by presence of CIND at baseline, (B) to death by number of cardiovascular risk
factors, (C) to dementia by number of cardiovascular risk factors and (D) to death or dementia by number of cardiovascular risk factors.
The mean number of days from stroke to dementia or death in the non-demented and DSM IV demented groups was 1483  922 and
1059  676 (P = 0.001).
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subjects (P40.05). We also found that given the presence of
clinical dementia, the majority of the post-stroke cases (not de-
mented at baseline) fulﬁlled currently used criteria for vascular
dementia. There was no particular distribution of the vascular ter-
ritory of the stroke or frequencies of the apolipoprotein "4 allele
that differentiated demented and non-demented subjects (data
not shown).
Further routine analysis of the pathological data indicated that
there was a greater number of individuals with Braak stage III or
higher among the demented cases, who also tended to exhibit a
higher proportion of microinfarctions (Table 4). The six cases that
were demented at baseline had a diagnosis of vascular dementia
(n = 3) and mixed dementia (n = 3) with both Alzheimer’s disease
and vascular dementia features (Table 4). Among the 56 cases
with post-mortem examination, 14 subjects (n = 6 with dementia)
had a MRI scan at baseline. The averaged left and right medial
temporal lobe atrophy score was signiﬁcantly greater (t = 2.7;
P = 0.02) in those with (medial temporal lobe atrophy = 3.8,
SD  1.0) versus without (medial temporal lobe atrophy 2.3,
SD  1.2) dementia at death. Baseline medial temporal lobe atro-
phy in this group also signiﬁcantly correlated with baseline
CAMCOG score (Pearson r = 0.63; P 0.011). There were signiﬁ-
cant differences in the last CAMCOG scores between those
with and without dementia at death (mean and SD, 88  7 and
68  11, P = 0.011). However, there were no differences in
the mean brain weights, Braak staging or burden of infarcts be-
tween these demented and non-demented MRI scanned groups
(P40.05).
Discussion
Our unique large study in older (475 years age) stroke survivors
in the North East of England reveals incidence and predictors of
delayed post-stroke dementia during up to 8 years of follow-up in
a hospital-based cohort of survivors of ﬁrst or recurrent stroke.
Having excluded those with pre-stroke dementia or a Mini-
Mental State Examination score 524 at 3 months post-stroke,
we found that almost 10% of these older participants developed
post-stroke dementia between 3 and 15 months after the stroke.
In the recent meta-analysis studies of post-stroke dementia in
22 separate cohorts (Pendlebury and Rothwell, 2009a), prevalence
of post-stroke dementia up to 1 year was 20.3% in hospital-based
Table 4 Neuropathological diagnoses of dementia in post-stroke survivors
Variable Post-stroke no
dementia
Incident dementia Dementia at baseline P-values*
No of cases 27 23 6 –
Age 84  48 8  58 5  8 P = 0.009 PSND versus
ID
Gender 15M/12F 12M/11F 3M/3F –
CAMCOG (highest) 92  68 2  95 8  11 P = 0.000 PSND versus
ID; versus DBaseline
CAMCOG (last) 89  65 9  23 31  33 P = 0.000 PSND versus
ID; versus DBaseline
CDR 0.1  0.4 1.4  0.9 3.0  0 P = 0.000 PSND versus
ID; versus DBaseline
Duration of survival (days from
baseline stroke to death)
1606  857 1304  811 nd P40.05
Brain weight 1267  118 1229  152 1219  69 P40.05
Number of infarcts 3.9  2.0 4.5  2.8 6.2  3.9 P40.05
Microinfarction (4three lesions
in four regions)
41% 50% 50% P = 0.05 PSND versus
ID
CERAD score 1.3  0.7 0.9  0.9 1.7  1.5 P40.05
Braak staging 2.5  1.3 2.6  1.1 3.7  2.6 P40.05
Neurodegenerative pathology
(at least one type)
30% 48% 50% P = 0.05 PSND versus
ID
Diagnosis PSND (n = 27) Vascular dementia
(n = 18); mixed:
ATP with
cerebrovascular
disease (n = 2),
LBP (n = 1),
FTLD (n = 1),
or PSP (n =1 )
Vascular dementia
(n = 3); mixed
Alzheimer’s disease
with cerebrovascular
disease (n =3 )
Values are mean  SD, unless noted otherwise.
ATP = Alzheimer type pathology; CDR = clinical dementia rating; DBaseline = dementia at baseline; FTLD = frontotemporal lobar degeneration; ID = incident dementia;
LBP = Lewy body pathology; n=number of autopsied subjects (total n = 56); nd = not deﬁned; PSND = post-stroke no dementia; PSP = progressive supranuclear palsy.
Mixed = vascular and neurodegenerative pathology.
There were no differences in the distribution of apolipoprotein E genotypes with the demented versus non-demented groups.
*P-values for two independent samples, Mann–Whitney U test or Chi-square analysis.
3720 | Brain 2011: 134; 3713–3724 L. M. Allan et al.studies, which included ﬁrst or recurrent stroke, substantially
higher than in our cohort. However, the hospital-based studies in-
cluded people with early post-stroke dementia (i.e. at 3 months),
in whom we believe dementia may have begun before the stroke.
In support of this view are the ICD 10 criteria, which require a
symptom duration of 6 months before making the diagnosis of
dementia. We excluded these individuals and only assessed
delayed post-stroke dementia occurring in the year after the ﬁrst
3 months. Thus, although our cohort included patients with recur-
rent stroke, it was more similar to the two population-based stu-
dies of ﬁrst-ever stroke, in which one also began measurement
after 3 months (Kokmen et al., 1996), where prevalence of post-
stroke dementia was 7.0%, and another (Kase et al., 1998) prob-
ably excluded more patients with pre-stroke dementia on the basis
of the pre-stroke Mini-Mental State Examination (prevalence
12.2%), and so our cohort concords with rates of post-stroke
dementia found where pre-stroke, or early post-stroke dementia
were effectively excluded.
During the mean follow-up period of 3.79 years, we found that
24% of participants succumbed to delayed post-stroke dementia.
Thus, the cumulative incident dementia rate, calculated to be
6.32 cases per 100 person years, was higher than those of recent
studies showing 6.6 and 25.5% cases for mean follow-up of
3.4 and 5.1 years, respectively (Melkas et al., 2009;
Narasimhalu et al., 2009). An obvious explanation for the differ-
ences relates to age. In these previous studies, stroke sur-
vivors were younger than in our study, with a mean age of 60
(Narasimhalu et al., 2009) and 72 years (Melkas et al., 2009)
while our study was 80  4 years. Our analysis showed that
although the effect of age on dementia alone was not signiﬁcant,
older age was associated with higher mortality and the combined
outcome of death or dementia. The older baseline age of our
subjects may have attenuated our ability to show an effect of
age on dementia. We did note that patients with CIND were
older than those without CIND (data not shown), and CIND did
predict dementia. This is in agreement with several studies to date
(Altieri et al., 2004; Bejot et al., 2011) and supports the view that
age is the strongest risk for all types of dementia, as well as
stroke-associated cerebral impairment.
Our ﬁndings revealed that CIND at 3 months post-stroke
(deﬁned as 580 total score) is a signiﬁcant predictor of long-term
incidence of dementia. This corroborates with previous studies
showing that moderate CIND or vascular mild cognitive impair-
ment post-stroke consistently predict progression to post-stroke
dementia (Ingles et al., 2002; Srikanth et al., 2006; Melkas
et al., 2009; Narasimhalu et al., 2009; Sachdev et al., 2009)
independently of pre-stroke cognitive impairment (Reitz et al.,
2008). These observations suggest that poor cognitive function
after the stroke is indicative of ongoing cognitive decline or that
once a particular threshold of cognitive change is breached, re-
covery from it is impossible. Furthermore, in accord with recent
studies (Narasimhalu et al., 2009; Oksala et al., 2009; Sachdev
et al., 2009), we also noted that the presence of either executive
dysfunction or global memory deﬁcits at baseline more than
doubled the risk of dementia after stroke. Although we did not
specify all the individual domains including attention, speed pro-
cessing or visuospatial and constructional abilities, we expected
that in this age group incident dementia would encompass several
executive function features that might adversely inﬂuence long-
term survival after stroke, even after adjustment of physical health
risk factors (Barba et al., 2002). Although we found that baseline
CIND and poor executive function predicted poorer survival, in
multivariate analyses, these factors were not retained, in contrast
to Melkas et al. (2009) who found that post-stroke dementia
predicted poor survival. We are uncertain of the cause of our
ﬁnding, but perhaps physical health factors outweigh dementia
in determining survival in an older cohort.
The effects of depression were slightly different from those of
cognitive impairment. Partly keeping with recent studies suggest-
ing depressed mood or depression after stroke is associated with
disability (Willey et al., 2010), cardiovascular events and incident
dementia (Peters et al., 2010), we noted that baseline depression
was a predictor of death, dementia and death or dementia in older
post-stroke survivors. In multivariate analyses, it was retained in
the models predicting death or the combined endpoint of death
and dementia, but not dementia alone. The mechanism by which
depression leads to poor survival, and its interaction with demen-
tia, urgently require further investigation.
Multivariate analyses revealed that presence of three or more
cardiovascular risk factors, increased risk of dementia or death by
4-fold in our elderly stroke patient population. Our observations
contrast with a recent systematic review (Savva and Stephan,
2010) where authors concluded that the effect of stroke on
dementia incidence in the population is explained by recurrent
stroke rather than cardiovascular risk factors. A limitation of our
study is that it was not possible within the resources of the study
to establish, with great accuracy, whether further strokes had
occurred at each follow-up and so this information is not available
to us. It is possible that the effect of multiple risk factors may have
been mediated via an increased rate of recurrent stroke. It is likely
that our subjects did go on to have further strokes, indeed the
post-mortem ﬁndings of substantial vascular pathology support
the argument that subsequent dementia is due to ongoing vascu-
lar pathology, including both macro- and microvascular disease.
However, one aim was to examine whether modiﬁable risk factors
known at the time of the index stroke would be useful in predict-
ing dementia outcomes. Our results indicate to clinicians at the
point of stroke assessment that the number of vascular risk factors
is important for future outcome, matters that can be acted upon
at that time, and plausibly inﬂuential in outcome. In contrast,
where reports indicate that outcome depends on further stroke,
the clinician will go back to the question, ‘what causes further
stroke that I can do something about?’ This does beg the question
of whether multiple vascular risk factors should be addressed to
prevent post-stroke dementia, and we believe that trials of mul-
tiple interventions for vascular risk factors should be undertaken as
soon as possible. In addition, our multivariate analyses suggest
that it is the accumulation of vascular risk factors that is particu-
larly detrimental for cognitive status in old age. A number of
studies have found signiﬁcant effects of individual vascular risk fac-
tors in both early and delayed post-stroke dementia, but have not
examined their cumulative effect, e.g. a population-based study
(Bejot et al., 2011) showed patients with post-stroke dementia
had a higher prevalence of several vascular risk factors including
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infarction and history of transient ischaemic attacks. However,
such associations have not been widely found in other studies
(Censori et al., 1996; Inzitari et al., 1998; Pohjasvaara et al.,
1998; Barba et al., 2000; Reitz et al., 2008). The 24-year study
(Bejot et al., 2011) also indicated that prevalence of post-stroke
dementia associated with lacunar stroke was seven times higher
than other types of stroke, including intracerebral haemorrhage.
Even though we had noted the arterial territories of the initial
strokes we did not have enough subjects to assess which types
or arterial territories were more prevalent in post-stroke dementia
cases.
The meta-analysis (Pendlebury and Rothwell, 2009a) reported
that neither hypertension nor previous ischaemic heart disease was
associated with post-stroke dementia, although recurrent strokes
were. In this context, the Rotterdam study found that an associ-
ation between incident stroke and risk of subsequent dementia
was independent from all other assessed risk factors for cognitive
decline including vascular disease factors such as hypertension,
diabetes, body mass index and apolipoprotein E "4 (Reitz et al.,
2008). While different cohort ages and sizes may explain the con-
ﬂicting results regarding the individual risk factors, or whether
their cumulative effect is examined, these ﬁndings collectively em-
phasize that implementation of secondary prevention measures
and sustained treatment strategies to control the risk of further
strokes or vascular disease in stroke survivors are imperative
(Mackowiak-Cordoliani et al., 2005). In the absence of other
effective neurotransmission-based therapies, enhancement of cho-
linergic systems may also prove useful (Roman and Kalaria, 2006).
In this age group, we also showed that the risk of dementia
remains increased even after initial improvements (Ballard et al.,
2003a; del Ser et al., 2005) or stability (Tham et al., 2002). This
could be related to factors other than those assessed in this study.
It is plausible that factors such as initial intellectual abilities, level of
education or anatomical variables such as brain size, structural
integrity of the temporal lobe or the white matter at inception,
contribute to the greater decline in some stroke patients.
One of the main strengths of our study is that unlike previous
studies (Pendlebury, 2009), we provide neuropathological diagno-
sis on a sizeable number of stroke survivors. We were surprised to
discover that there was no difference in the mean survival period
between the demented and non-demented stroke survivors who
came to autopsy. This was not expected given that clinical studies
(Henon et al., 2003; Oksala et al., 2009; Brodaty et al., 2010;
Narasimhalu et al., 2011) have indicated post-stroke cognitive
deﬁcits increase mortality rates and so demented subjects should
exhibit shorter survival. We deem this is a relatively small sample
(n = 25 each group) and may not hold true in a larger sample.
Given that accurate clinical diagnosis of vascular dementia and
Alzheimer’s disease has proved difﬁcult in the light of autopsy
results (Bowler et al., 1998; Nolan et al., 1998; Kalaria, 2002),
we initially concentrated on diagnosing any type of dementia after
stroke. However, it is important to consider the mechanisms caus-
ing dementia after stroke injury. Our previous imaging studies (in
a subset of this post-stroke cohort) had suggested the presence of
an Alzheimer’s disease component in those who exhibit delayed
dementia after stroke (Firbank et al., 2007). Although the subjects
were found to have frontal lobe white matter abnormalities
(Firbank et al., 2011) consistent with the Alzheimer’s disease scen-
ario (Burton et al., 2009), they exhibited medial temporal lobe
atrophy as a prominent feature associated with cognitive decline
after stroke (Bombois et al., 2008; Pendlebury and Rothwell,
2009a). Our ﬁndings from prospectively assessed individuals
scanned in life and then examined at autopsy supports this
notion that medial temporal lobe atrophy is associated with vas-
cular dementia or stroke-related dementia although it may not be
as apparent as in Alzheimer’s disease (Jagust et al., 2008; Burton
et al., 2009).
In our study most of the stroke survivors who were
clinically demented at autopsy had high a burden of vascular
pathology in the general absence of signiﬁcant Alzheimer-
type pathology (Kalaria et al., 2004). While stroke survivors
may not be completely free of Alzheimer pathology or amyloid-b
accumulation (Lewis et al., 2006; Mok et al., 2010), these data
indicated that elderly stroke survivors, at least in the 475 age
group, are likely to develop vascular dementia with minimal
Alzheimer’s disease features (Altieri et al., 2004). It is possible
that stroke may trigger or unmask neurodegenerative processes
characterized by primary pathologies (Bowler et al., 1998;
Hsiung et al., 2006). On the other hand, our pathological ﬁndings
are perhaps not surprising when considering the clinical inclusion
criteria for each patient (Roman et al., 1993; Chui et al., 2000).
They should have been cognitively intact despite being at least 75
years of age and had experienced at least one recent clinically
detectable stroke. With few exceptions, the cerebrovascular
changes in the brain appeared to explain the dementia better
than the meagre presence of primary neurodegenerative disease
pathology. Nonetheless, the clinical ﬁndings in the autopsied sub-
population indicate that the initial cognitive abilities after the
stroke and age at death remain strong predictors of dementia
even when the standard neuropathological lesions are taken into
account.
Conclusion
Our report indicates that the prognosis for survival and cognitive
function in older stroke survivors after 5 years from index stroke
remains very poor. An increased number of cardiovascular risk
factors worsens cognitive status after stroke whereby those who
become demented largely appear to succumb to vascular demen-
tia. Our results have strong implications for secondary prevention
to abate vascular disease. They also suggest that the treatment or
reduction of vascular risk factors in old age requires clinical trials
with more than a single agent approach, especially if the burden
of vascular dementia or vascular cognitive impairment is to be
reduced (Hachinski et al., 2006).
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